• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Matthew R. Smith, MD, PhD

Publications

  • Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR.A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.Clin Cancer Res. 2013 Apr 3.
    23553848
  • Keating NL, Liu PH, O'Malley AJ, Freedland SJ, Smith MR.Androgen-deprivation Therapy and Diabetes Control Among Diabetic Men with Prostate Cancer.Eur Urol. 2013 Feb 22.
    23453420
  • Saylor PJ, Smith MR, O'Malley AJ, Keating NL.Androgen-deprivation Therapy and Risk for Biliary Disease in Men with Prostate Cancer.Eur Urol. 2013 Feb 12.
    23428068
  • Lee RJ, Smith MR.Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer.Cancer J.;19(1):90-8.
    23337762
  • Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, .Abiraterone in metastatic prostate cancer without previous chemotherapy.N Engl J Med. 2013 Jan 10;368(2):138-48.
    23228172
  • Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K.New and emerging therapies for bone metastases in genitourinary cancers.Eur Urol. 2013 Feb;63(2):309-20.
    23201471
  • Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS.Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.J Urol. 2013 Jan;189(1 Suppl):S45-50.
    23234631
  • Keating NL, O'Malley A, Freedland SJ, Smith MR.Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.Journal of the National Cancer Institute. 2012 Oct 3;104(19):1518-23.
    23210129
  • Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M.Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial.J Clin Oncol. 2012 Nov 19.
    23169517
  • Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA.Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.Cancer Discovery. 2012 Nov;2(11):995-1003.
    23093251
  • Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD.Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer.J Nucl Med. 2012 Nov;53(11):1670-5.
    22984218
  • Morgans AK, Smith MR.Bone-targeted agents: preventing skeletal complications in prostate cancer.Urol Clin North Am. 2012 Nov;39(4):533-46.
    23084529
  • Smith MR.Skeletal-related events in prostate cancer.Clin Adv Hematol Oncol. 2012 Aug;10(8):535-6.
    23073052
  • Morgans AK, Smith MR, O'Malley AJ, Keating NL.Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.Cancer. 2012 Oct 12.
    23065626
  • Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, Leder BZ, Goessl C.Sarcopenia during androgen-deprivation therapy for prostate cancer.J Clin Oncol. 2012 Sep 10;30(26):3271-6.
    22649143
  • Lipton A, Smith MR, Ellis GK, Goessl C.Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.Clin Med Insights Oncol. 2012;6:287-303.
    22933844
  • D'Amico AV, Smith MR.Clinical decisions. Screening for prostate cancer.N Engl J Med. 2012 Aug 16;367(7):e11.
    22894598
  • Saylor PJ, Karoly ED, Smith MR.Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer.Clin Cancer Res. 2012 Jul 1;18(13):3677-85.
    22589396
  • Saylor PJ, Keating NL, Freedland SJ, Smith MR.Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.Drugs. 2011 Feb 12;71(3):255-61.
    21319864
  • Lee RJ, Saylor PJ, Smith MR.Contemporary therapeutic approaches targeting bone complications in prostate cancer.Clin Genitourin Cancer. 2010 Dec 1;8(1):29-36.
    21208853
  • Lee RJ, Saylor PJ, Smith MR.Treatment and prevention of bone complications from prostate cancer.Bone. 2011 Jan 1;48(1):88-95.
    20621630
  • Smith MR, Martin TJ.Foreword: Skeletal Complications of Cancer.Bone. 2011 Jan 1;48(1):5.
    20950719
  • Hatoum HT, Lin SJ, Guo A, Lipton A, Smith MR.Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis.Curr Med Res Opin. 2011 Jan;27(1):55-62.
    21083514
  • Saad F, Eastham JA, Smith MR.Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer.Urol Oncol. 2010 Dec 15.
    21163673
  • Smith MR, Cook R, Lee KA, Nelson JB.Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.Cancer. 2010 Nov 16.
    21082701
  • Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ.Metastasis and bone loss: Advancing treatment and prevention.Cancer Treat Rev. 2010 Dec;36(8):615-20. Review.
    20478658
  • Smith MR, Klotz L, Persson BE, Olesen TK, Wilde AA.Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer.J Urol. 2010 Dec;184(6):2313-9.
    20952020
  • Coen JJ, Feldman AS, Smith MR, Zietman AL.Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?.BJU Int. 2010 Sep 22.
    20860650
  • Kim HS, Moreira DM, Smith MR, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ.A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.BJU Int. 2010 Sep 22.
    20860651
  • Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS.Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.J Urol. 2010 Oct;184(4):1316-21.
    20723926
  • Vallet S, Smith MR, Raje N.Novel bone-targeted strategies in oncology.Clin Cancer Res. 2010 Aug 15;16(16):4084-93.
    20643782
  • Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL.The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer.BJU Int. 2010 May;105(10):1417-22. Review.
    20346051
  • Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR.Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer.J Urol. 2010 Jun;183(6):2200-5.
    20399451
  • Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, .Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology.CA Cancer J Clin.;60(3):194-201. Review.
    20124400
  • Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S.Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.Sci Transl Med. 2010 Mar 31;2(25):25ra23.
    20424012
  • Faris JE, Smith MR.Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.Curr Opin Endocrinol Diabetes Obes. 2010 Jun;17(3):240-6. Review.
    20404727
  • Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI.Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer.J Clin Oncol. 2010 Mar 20;28(9):1496-501.
    20159814
  • Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ.Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy.J Clin Oncol. 2010 Mar 20;28(9):1481-8.
    20159824
  • Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F.NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas.J Natl Compr Canc Netw. 2010 Mar;8(3):288-334.
    20202462
  • Efstathiou JA, Shipley WU, Zietman AL, Smith MR.Hormonal therapies: ADT for prostate cancer: true love or heartbreak?.Nat Rev Clin Oncol. 2010 Mar;7(3):130-2.
    20190794
  • Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, .Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the american heart association, american cancer society, and american urological association: endorsed by the american society for radiation oncology.Circulation. 2010 Feb 16;121(6):833-40.
    20124128
  • Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC.NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer.J Natl Compr Canc Netw. 2010 Feb;8(2):162-200.
    20141676
  • Saylor PJ, Smith MR.Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.J Natl Compr Canc Netw. 2010 Feb;8(2):211-23.
    20141678
  • Smith MR, Kantoff PW.Changes in PSA kinetics after DNA vaccine therapy-not so fast!.J Clin Oncol. 2010 Feb 1;28(4):e58; author reply e59.
    20008614
  • Keating NL, O'Malley AJ, Freedland SJ, Smith MR.Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.Journal of the National Cancer Institute. 2010 Jan 6;102(1):39-46.
    19996060
  • Smith MR, Blake AJ, Hayes CJ, Stevens MF, Moody CJ.Carbene reactivity of 4-diazo-4H-imidazoles toward nucleophiles and aromatic compounds.J Org Chem. 2009 Dec 18;74(24):9372-80.
    19921793
  • Isbarn H,Boccon-Gibod L,Carroll PR,Montorsi F,Schulman C,Smith MR,Sternberg CN,Studer UE.Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks.Eur Urol. 2009 Jan;55(1):62-75. Review.
    18945543
  • Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C, Leder BZ, Goessl C.Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.J Urol. 2009 Dec;182(6):2670-5.
    19836774
  • Saylor PJ, Keating NL, Smith MR.Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.J Gen Intern Med. 2009 Nov;24 Suppl 2:S389-94. Review.
    19838837
  • Saylor PJ, Smith MR.Prostate cancer: How can we improve the health of men who receive ADT?.Nat Rev Urol. 2009 Oct;6(10):529-31.
    19806171
  • Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE.Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.BMC Cancer. 2009;9:272.
    19660124
  • Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C, .Denosumab in men receiving androgen-deprivation therapy for prostate cancer.N Engl J Med. 2009 Aug 20;361(8):745-55.
    19671656
  • Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH.NCCN Task Force Report: Bone Health in Cancer Care.J Natl Compr Canc Netw. 2009 Jun;7 Suppl 3:S1-S32; quiz S33-S35.
    19555589
  • Saylor PJ,Smith MR.Metabolic complications of androgen deprivation therapy for prostate cancer.J Urol. 2009 May;181(5):1998-2006; discussion 2007-8. Review.
    19286225
  • Temel JS,Greer JA,Goldberg S,Vogel PD,Sullivan M,Pirl WF,Lynch TJ,Christiani DC,Smith MR.A structured exercise program for patients with advanced non-small cell lung cancer.J Thorac Oncol. 2009 May;4(5):595-601.
    19276834
  • Efstathiou JA,Bae K,Shipley WU,Hanks GE,Pilepich MV,Sandler HM,Smith MR.Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.J Clin Oncol. 2009 Jan 1;27(1):92-9.
    19047297
  • Coleman RE,Guise TA,Lipton A,Roodman GD,Berenson JR,Body JJ,Boyce BF,Calvi LM,Hadji P,McCloskey EV,Saad F,Smith MR,Suva LJ,Taichman RS,Vessella RL,Weilbaecher KN.Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.Clin Cancer Res. 2008 Oct 15;14(20):6387-95. Review.
    18927277
  • Smith MR.Osteoporosis in men with prostate cancer: now for the fracture data.J Clin Oncol. 2008 Sep 20;26(27):4371-2.
    18802147
  • Smith MR,Bae K,Efstathiou JA,Hanks GE,Pilepich MV,Sandler HM,Shipley WU.Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.J Clin Oncol. 2008 Sep 10;26(26):4333-9.
    18779620
  • Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR.Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02.Eur Urol. 2008 Oct;54(4):816-23.
    18243498
  • Smith MR.Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.Urol Oncol. 2008 Jul-Aug;26(4):420-5. Review.
    18593621
  • Coleman R,Brown J,Terpos E,Lipton A,Smith MR,Cook R,Major P.Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.Cancer Treat Rev. 2008 Nov;34(7):629-39. Review.
    18579314
  • Smith MR.Rapid testosterone cycling and chemotherapy for prostate cancer: a way forward or return to the past?.J Clin Oncol. 2008 Jun 20;26(18):2932-3.
    18565878
  • Michaelson MD,Cotter SE,Gargollo PC,Zietman AL,Dahl DM,Smith MR.Management of complications of prostate cancer treatment.CA Cancer J Clin. 2008 Jul-Aug;58(4):196-213. Review.
    18502900
  • Smith MR,O'Malley AJ,Keating NL.Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?.BJU Int. 2008 Jun;101(11):1335-6.
    18454791
  • Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F.Non-Hodgkin's Lymphomas.J Natl Compr Canc Netw. 2008 Apr;6(4):356-421.
    18433606
  • Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP.A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.BJU Int. 2008 May;101(9):1084-9.
    18399827
  • Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MR.Use of androgen deprivation therapy for metastatic prostate cancer in older men.BJU Int. 2008 May;101(9):1077-83.
    18190632
  • Smith MR, Malkowicz SB, Chu F, Forrest J, Sieber P, Barnette KG, Rodriquez D, Steiner MS.Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.J Clin Oncol. 2008 Apr 10;26(11):1824-9.
    18398147
  • Smith MR,Lee H,McGovern F,Fallon MA,Goode M,Zietman AL,Finkelstein JS.Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.Cancer. 2008 May 15;112(10):2188-94.
    18348297
  • Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE.Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.J Thorac Oncol. 2008 Mar;3(3):228-36.
    18317064
  • Smith MR, Lee H, Fallon MA, Nathan DM.Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.Urology. 2008 Feb;71(2):318-22.
    18308111
  • Pirl WF, Greer JA, Goode M, Smith MR.Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy.Psychooncology. 2008 Feb;17(2):148-53.
    17443645
  • Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M.Isolation of rare circulating tumour cells in cancer patients by microchip technology.Nature. 2007 Dec 20;450(7173):1235-9.
    18097410
  • Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR.Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.Cancer. 2007 Dec 15;110(12):2691-9.
    17999404
  • Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman ML.Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.Int J Cancer. 2007 Dec 15;121(12):2661-7.
    17721994
  • Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR.Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.J Clin Oncol. 2007 Mar 20;25(9):1038-42.
    17369566
  • Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antrs L, Smith M, Neary MP, Duh MS.The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.Cancer. 2007 Mar 15;109(6):1090-6.
    17311345
  • Smith MR.Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer.Clin Cancer Res. 2007 Jan 1;13(1):241-5.
    17200361
  • Smith MR.Treatment-related osteoporosis in men with prostate cancer.Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6315s-6319s. Review.
    17062721
  • Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L.Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6209s-6212s.
    17062702
  • Smith MR.Selective estrogen receptor modulators to prevent treatment-related osteoporosis.Rev Urol. 2005;7 Suppl 3:S30-5.
    16985877
  • Keating NL, O'Malley AJ, Smith MR.Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.J Clin Oncol. 2006 Sep 20;24(27):4448-56.
    16983113
  • Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR.Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.Cancer. 2006 Aug 1;107(3):530-5.
    16804927
  • Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW.Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.J Clin Oncol. 2006 Jun 20;24(18):2723-8.
    16782912
  • Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF.Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.J Clin Oncol. 2006 Jul 1;24(19):3107-12.
    16754937
  • Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR.Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3361-7.
    16740758
  • Bevers TB, Anderson BO, Bonaccio E, Borgen PI, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Helvie M, Hoover S, Krontiras H, Shaw S, Singletary E, Sugg Skinner C, Smith ML, Tsangaris TN, Wiley EL, Williams C.Breast cancer screening and diagnosis.J Natl Compr Canc Netw. 2006 May;4(5):480-508.
    16687096
  • Smith MR.Markers of bone metabolism in prostate cancer.Cancer Treat Rev. 2006;32 Suppl 1:23-6. Review.
    16680835
  • Smith MR, Joshi I, Jin F, Al-Saleem T.Murine model for mantle cell lymphoma.Leukemia. 2006 May;20(5):891-3.
    16525491
  • Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J.Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2006 Mar;4(3):258-310.
    16507273
  • Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA.Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.Expert Opin Investig Drugs. 2006 Mar;15(3):293-305. Review.
    16503765
  • Smith MR.Therapy Insight: osteoporosis during hormone therapy for prostate cancer.Nat Clin Pract Urol. 2005 Dec;2(12):608-15; quiz 628. Review.
    16474548
  • Smith MR, Lee H, Nathan DM.Insulin sensitivity during combined androgen blockade for prostate cancer.J Clin Endocrinol Metab. 2006 Apr;91(4):1305-8.
    16434464
  • Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J.Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.J Urol. 2006 Jan;175(1):136-9; discussion 139.
    16406890
  • Michaelson MD, Smith MR.Bisphosphonates for treatment and prevention of bone metastases.J Clin Oncol. 2005 Nov 10;23(32):8219-24.
    16278476
  • Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL.Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.J Clin Oncol. 2005 Nov 1;23(31):7897-903.
    16258089
  • Lee H, McGovern K, Finkelstein JS, Smith MR.Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma.Cancer. 2005 Oct 15;104(8):1633-7.
    16116596
  • Smith MR, Nelson JB.Future therapies in hormone-refractory prostate cancer.Urology. 2005 May;65(5 Suppl):9-16; discussion 17.
    15885273
  • Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS.Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.J Clin Oncol. 2005 May 1;23(13):2918-25.
    15860850
  • Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW.A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.Clin Cancer Res. 2005 Jan 1;11(1):284-9.
    15671557
  • Michaelson MD, Smith MR, Talcott JA.Prostate cancer (metastatic).Clin Evid. 2003 Dec(10):1012-22.
    15555135
  • Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ.Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer.J Clin Oncol. 2004 Sep 15;22(18):3705-12.
    15289492
  • Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS.Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.J Clin Oncol. 2004 Jul 1;22(13):2546-53.
    15226323
  • Michaelson MD, Marujo RM, Smith MR.Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer.Clin Cancer Res. 2004 Apr 15;10(8):2705-8.
    15102674
  • Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW.Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.Urology. 2003 Jul;62(1):99-104.
    12837431
  • Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.J Urol. 2003 Jun;169(6):2008-12.
    12771706
  • Smith MR, Fallon MA, Goode MJ.Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.Urology. 2003 Jan;61(1):127-31.
    12559282
  • Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW.Selective aromatase inhibition for patients with androgen-independent prostate carcinoma.Cancer. 2002 Nov 1;95(9):1864-8.
    12404279
  • Smith MR, Kantoff PW.Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer.Invest New Drugs. 2002 May;20(2):195-200.
    12099579
  • Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW.Changes in body composition during androgen deprivation therapy for prostate cancer.J Clin Endocrinol Metab. 2002 Feb;87(2):599-603.
    11836291
  • Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS.Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.N Engl J Med. 2001 Sep 27;345(13):948-55.
    11575286